Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 864070-44-0] Empagliflozin

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-15409
Brand:	MCE
CAS:	864070-44-0

Overview

MDL	MFCD22566222
Molecular Weight	450.91
Molecular Formula	C23H27ClO7
SMILES	ClC(C=CC([C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)=C2)=C2CC(C=C3)=CC=C3O[C@H]4CCOC4

For research use only. We do not sell to patients.

41 Publications Citing Use of MCE

[1]Basic Res Cardiol. 2022 Sep 28;117(1):47.
[2]Protein Cell. 2022 May;13(5):336-359.
[3]Diabetologia. 2017 Mar;60(3):568-573.
[4]Cardiovasc Diabetol. 2023 Feb 6;22(1):27.
[5]Acta Biomater. 2022 Feb 18;S1742-7061(22)00096-4.
[6]Free Radic Biol Med. 2023 Feb 1;195:89-102.
[7]Free Radic Biol Med. 2022.
[8]Antioxidants (Basel). 2022 Apr 19;11(5):799.
[9]Biochem Pharmacol. 2018 Jun;152:45-59.
[10]J Inflamm Res. 2021 May 31;14:2277-2287.
[11]J Am Heart Assoc. 2022 Feb 15;11(4):e023800.
[12]Int J Mol Sci. 2021 Jan 15;22(2):E818.
[13]Front Pharmacol. 23 March 2022.
[14]Front Pharmacol. 29 April 2021.
[15]Vascul Pharmacol. 2018 Oct;109:56-71.
[16]Biomolecules. 2022, 12(9), 1176.
[17]Cardiovasc Drugs Ther. 2021 Apr 22.
[18]Mol Cell Endocrinol. 2019 Aug 20;494:110487.
[19]Life Sci. 2019 Sep 1;232:116622.
[20]Eur J Pharm Sci. 2021, 105788.
[21]Am J Pathol. 2022 Oct 12;S0002-9440(22)00311-X.
[22]Renal Failure. 13 Sep 2022.
[23]Am J Physiol Renal Physiol. 2021 Aug 1;321(2):F149-F161.
[24]J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:227-33.
[25]J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 1;1000:22-8.
[26]Lipids Health Dis. 2021 Jan 12;20(1):5.
[27]Diabet Metab Synd Ob. 2021 Jan 18;14:227-240.
[28]Diabet Metab Synd Ob. 2020 Jun 12;13:1953-1967.
[29]Int J Med Sci. 2018 Jun 13;15(9):937-943.
[30]Bioengineered. 2021 Dec;12(2):9356-9366.
[31]Biomed Chromatogr. 2019 Nov;33(11):e4663.
[32]Biomed Chromatogr. 2016 Oct;30(10):1549-55.
[33]Annals of the Romanian Society for Cell Biology. 2021 Mar 15.
[34]Research Square Preprint. 2021 Feb.
[35]European Journal of Molecular & Clinical Medicine. 2020, 7(1): 4324-4334.
[36]Circ Heart Fail. 2020 Jan;13(1):e006277.
[37]Medical Science, Pediatrics University of Alberta. 2019 Dec.
[38]Cell Physiol Biochem. 2019;53(5):865-886.
[39]JACC Basic Transl Sci. 2019 Sep 4;4(5):575-591.
[40]Department of Chemical Engineering. McGill University. 2018 Jan.
[41]JACC Basic Transl Sci. 2017 Aug;2(3):347-354.

Summary

Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 ( SGLT-2 ) inhibitor with an IC ₅₀ of 3.1 nM for human SGLT-2 ^[1] .

IC50 & Target

IC50: 3.1 nM (SGLT-2), 1.1 μM (SGLT-5), 2 μM (SGLT-6), 8.3 μM (SGLT-1), 11 μM (SGLT-4) ^[1]

In Vitro

Empagliflozin is a potent and competitive SGLT-2 inhibitor with an excellent selectivity profile and the highest selectivity window of the tested SGLT-2 inhibitors over hSGLT-1. Empagliflozin inhibits the uptake of [ ¹⁴ C]-alpha-methyl glucopyranoside (AMG) via hSGLT-2 in a dose-dependent manner with an IC ₅₀ of 3.1 nM, but is less potent for other SGLTs (IC ₅₀ range: 1100-11000 nM). [ ³ H]-Empagliflozin displays a high affinity for SGLT-2 with a mean K _d of 57±37 nM in the absence of glucose in kinetic binding experiments ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Glucose intolerance is significantly improved after 8 days of Empagliflozin treatment at either dose (3mg/kg Empagliflozin 3058±180 vs 10mg/kg Empagliflozin 3090±219). Therefore, acute treatment with Empagliflozin has a beneficial effect on hyperglycemia and glucose intolerance. Since there are no significant differences in blood glucose homeostasis with the two different doses of Empagliflozin, and random blood glucose levels of T1DM mice are significantly improved by 3mg/kg of Empagliflozin, the effect of the lower dose of Empagliflozin (3mg/kg) is investigated on preserving β-cell mass and function ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04796428	Center for Outcomes Research and Clinical Epidemiology, Italy\|Italian Society of Diabetology	Diabetes Mellitus, Type 2	June 30, 2021	Phase 4
NCT04345796	Asan Medical Center\|Chong Kun Dang Pharmaceutical Company	Tricuspid Regurgitation\|Right Ventricular Dilatation	February 15, 2021	Phase 3
NCT04937816	Boehringer Ingelheim	Diabetes Mellitus, Type 2	June 1, 2021
NCT01811953	Boehringer Ingelheim	Healthy	March 2013	Phase 1
NCT03591991	Chinese PLA General Hospital	Reperfusion Injury, Myocardial	October 1, 2018	Not Applicable
NCT03437330	University Hospital Tuebingen	Type2 Diabetes Mellitus	October 27, 2021	Phase 4
NCT04970108	EMS	Hypertension Associated\|Type II Diabetes Mellitus	August 2023	Phase 3
NCT05174507	University Hospital, Basel, Switzerland	Postprandial Hypoglycemia	July 2022	Phase 2
NCT05359341	Sadat City University\|Beni-Suef University	Diabete Type 2	September 20, 2020	Not Applicable
NCT04930627	Children´s Memorial Health Institute, Poland\|Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw	Glucose 6 Phosphatase Deficiency	July 2021	Phase 2
NCT05614115	University of Utah\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	End-stage Kidney Disease\|Kidney Disease, Chronic\|Dialysis\|Diabetic\|Non-diabetic\|Kidney Dysfunction\|Kidney Failure\|Hemodialysis	December 15, 2022	Phase 1
NCT01257334	Taipei Medical University WanFang Hospital	Type 2 Diabetes	September 2010	Phase 3
NCT01719003	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2\|Hyperglycemia	October 2012	Phase 3
NCT05373680	Tanta University\|Mansoura University	Renal Insufficiency, Chronic	January 1, 2022	Phase 2\|Phase 3
NCT02453555	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	May 14, 2015	Phase 3
NCT03193684	The University of Texas Health Science Center at San Antonio\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Hepatic Glucose Metabolism	May 20, 2018	Phase 4
NCT01422876	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	August 2011	Phase 3
NCT04447911	University Hospital, Basel, Switzerland\|Luzerner Kantonsspital\|Centre Hospitalier Universitaire Vaudois	Hyponatremia\|SIADH\|Liver Failure\|Kidney Failure	February 4, 2021	Phase 4
NCT04603508	EMS	Type 2 Diabetes Mellitus\|Dyslipidemia	March 2023	Phase 3
NCT02028767	Boehringer Ingelheim	Healthy	January 2014	Phase 1
NCT04986735	Hong Kong Children´s Hospital	Glycogen Storage Disease Type IB	August 8, 2021
NCT05081219	Wake Forest University Health Sciences	Mild Cognitive Impairment\|Cognitive Impairment\|Alzheimer Disease	October 14, 2021	Phase 2
NCT05580510	Instituto Nacional de Cardiologia Ignacio Chavez\|Boehringer Ingelheim laboratory	Congenital Heart Disease\|Heart Failure\|Heart Failure With Reduced Ejection Fraction	February 6, 2023	Phase 2\|Phase 3
NCT04602754	EMS	Dyslipidemia Associated With Type II Diabetes Mellitus	March 2023	Phase 3
NCT05109949	Centro Universitario de Ciencias de la Salud, Mexico	Diabetes Mellitus Type 2 Without Complication	March 30, 2020	Phase 3
NCT05073692	Kaiser Permanente\|Geisinger Clinic\|Henry Ford Health System\|HealthPartners Institute\|Patient-Centered Outcomes Research Institute	Type 2 Diabetes Mellitus\|Cardiovascular Diseases	July 1, 2021
NCT03629054	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	August 27, 2018	Phase 1
NCT02768220	Northwell Health	SGLT-2 Inhibitors\|Advanced Glycation End Products\|Diabetes	December 1, 2017	Phase 4
NCT01242176	Boehringer Ingelheim	Healthy	November 2010	Phase 1
NCT02752113	Institut für Pharmakologie und Präventive Medizin\|University of Erlangen-Nürnberg Medical School	Diabetes Mellitus Type 2	April 2016	Phase 3
NCT01011868	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	November 2009	Phase 2
NCT04061473	University Hospital, Gentofte, Copenhagen	Diabetes After Total Pancreatectomy	April 2, 2019	Not Applicable
NCT05282121	Boehringer Ingelheim	Liver Diseases\|Hypertension, Portal	May 26, 2022	Phase 2
NCT02964572	Yonsei University	Type2 Diabetes Mellitus	November 2016	Not Applicable
NCT00789035	Boehringer Ingelheim	Diabetes Mellitus, Type 2	October 2008	Phase 2
NCT01301742	Boehringer Ingelheim	Healthy	February 2011	Phase 1
NCT04735042	University of Pisa	Type 2 Diabetes\|Urinary Tract Infections	October 7, 2020
NCT04665284	Getz Pharma	Type II Diabetes Mellitus	June 1, 2019	Phase 4
NCT04381936	University of Oxford\|UK Research and Innovation\|National Institute for Health Research, United Kingdom\|Wellcome\|Bill and Melinda Gates Foundation\|Department for International Development, United Kingdom\|Health Data Research UK\|Medical Research Council Population Health Research Unit\|NIHR Clinical Trials Unit Support Funding\|NIHR Health Protection Research Unit in Emerging and Zoonotic Infections	Severe Acute Respiratory Syndrome	March 19, 2020	Phase 2\|Phase 3
NCT05605158	Tanta University	Non Alcoholic Steatohepatitis	November 2022	Phase 3
NCT03807440	Boehringer Ingelheim	Diabetes Mellitus, Type 2	August 26, 2019
NCT01392560	Boehringer Ingelheim	Diabetes Mellitus, Type 1	June 2011	Phase 2
NCT02729766	University Hospital, Basel, Switzerland	Inappropriate ADH Syndrome	March 2016	Phase 2\|Phase 3
NCT04509674	Boehringer Ingelheim\|Eli Lilly and Company	Myocardial Infarction	December 16, 2020	Phase 3
NCT05037695	University of Sao Paulo General Hospital	Diabetes Mellitus, Type 2\|Coronary Artery Disease\|Acute Kidney Injury	July 21, 2021	Phase 4
NCT03173963	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health Clinical Center (CC)	Diabetic Kidney Disease\|Diabetes Mellitus Type 2	May 27, 2017	Phase 3
NCT05057806	The University of Texas Health Science Center at San Antonio\|Doris Duke Charitable Foundation	Type2 Diabetes\|Heart Failure With Preserved Ejection Fraction	January 13, 2021	Early Phase 1
NCT05271162	Maria Sklodowska-Curie National Research Institute of Oncology\|Medical Research Agency, Poland	Cardiotoxicity	September 2022	Phase 3
NCT02182830	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2\|Hypertension	July 25, 2014	Phase 3
NCT03132181	RWTH Aachen University\|Boehringer Ingelheim	Diabetes Mellitus Type 2 (T2DM)	April 24, 2017	Phase 2
NCT04201496	Ananda Basu, MD\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Tandem Diabetes Care, Inc.\|DexCom, Inc.\|University of Virginia	Type 1 Diabetes	February 24, 2020	Phase 1
NCT05129722	The George Institute\|Victor Chang Cardiac Research Institute\|St Vincent´s Centre for Applied Medical Research	Heart Failure With Preserved Ejection Fraction	June 1, 2022	Phase 4
NCT03748810	Chungbuk National University Hospital	Type2 Diabetes	January 1, 2016
NCT04131582	Universidad de Guanajuato\|Hospital Regional de Alta Especialidad del Bajio	Prediabetic State\|Insulin Resistance	September 1, 2019	Phase 3
NCT01969747	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 1	November 2013	Phase 2
NCT03713190	University of Pisa	End Stage Renal Disease	September 10, 2018	Phase 2
NCT01276301	Boehringer Ingelheim	Healthy	January 2011	Phase 1
NCT02589639	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	October 28, 2015	Phase 4
NCT05493371	Amsterdam UMC, location VUmc	Idiopathic Pulmonary Arterial Hypertension	November 1, 2022	Phase 2
NCT02637973	The Deutsche Diabetes Forschungsgesellschaft e.V.\|Boehringer Ingelheim\|German Diabetes Center	Type 2 Diabetes\|Non-alcoholic Fatty Liver Disease	December 2015	Phase 4
NCT05182840	Boehringer Ingelheim	Kidney Disease, Chronic	January 11, 2022	Phase 2
NCT02414958	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 1	June 30, 2015	Phase 3
NCT03152552	Novartis Pharmaceuticals\|Novartis	Diabetes Mellitus and Heart Failure	July 25, 2017	Phase 2
NCT05465317	Boehringer Ingelheim	Diabetes Mellitus, Type 2	August 8, 2022
NCT02702011	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 1	March 20, 2016	Phase 2
NCT03560375	Tel-Aviv Sourasky Medical Center	Diabetes Mellitus, Type 2\|Sarcopenia\|Weight Loss\|Frailty	May 9, 2018	Phase 4
NCT03118336	Assistance Publique Hopitaux De Marseille	Type 2 Diabetes	June 16, 2017	Phase 3
NCT02230995	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	September 2014	Phase 1
NCT05020704	NHS Greater Glasgow and Clyde\|University of Glasgow	Myocardial Infarction	November 1, 2021	Phase 4
NCT01370005	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2\|Hypertension	June 2011	Phase 3
NCT05138575	University of Pennsylvania	Heart Failure With Preserved Ejection Fraction	January 24, 2022	Phase 2
NCT02798744	University of Leicester\|Loughborough University\|University Hospitals, Leicester	Diabetes Mellitus, Type 2	December 2016	Phase 4
NCT05042973	Jacob Moller\|Danish Heart Foundation\|Herlev and Gentofte Hospital\|University Hospital Bispebjerg and Frederiksberg\|Hillerod Hospital, Denmark\|Rigshospitalet, Denmark\|Odense University Hospital	Obesity\|Heart Failure	September 2, 2021	Phase 2
NCT02172261	Boehringer Ingelheim	Healthy	April 2009	Phase 1
NCT05359432	Getz Pharma	Type 2 Diabetes	July 1, 2020	Phase 4
NCT05013502	Stanford University	Liver Cirrhosis\|Cirrhosis\|Ascites\|Ascites Hepatic\|Sodium-Glucose Transporter 2 Inhibitors	November 15, 2021	Phase 1
NCT04195243	Centro Universitario de Ciencias de la Salud, Mexico	Type 2 Diabetes Mellitus	December 2, 2019	Phase 3
NCT05426525	Oregon State University\|Samaritan Health Services	PreDiabetes\|Prediabetic State\|Overweight and Obesity	July 2022	Phase 4
NCT03271879	Rambam Health Care Campus\|Boehringer Ingelheim	Heart Failure\|Diabetes Mellitus\|Arrythmia	February 15, 2018	Phase 4
NCT04497792	Research Institute for Complex Problems of Cardiovascular Diseases, Russia	Coronary Artery Disease\|Diabetes Mellitus\|Percutaneous Coronary Intervention	November 2016	Phase 4
NCT02985242	Hannover Medical School	Diabetes Mellitus, Type II	June 12, 2017	Phase 4
NCT03753087	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation\|Ministry of Health of the Russian Federation	Heart Failure, Diastolic\|Diabetes Mellitus, Type 2	January 16, 2019	Phase 4
NCT04461041	Unity Health Toronto\|Canadian Medical and Surgical Knowledge Translation Research Group\|Boehringer Ingelheim\|Applied Health Research Centre	Cardiovascular Diseases\|Left Ventricular Hypertrophy	April 1, 2021	Phase 4
NCT04911660	University Hospital Inselspital, Berne\|Boehringer Ingelheim\|University of Bern	Kidney Stone	August 25, 2021	Phase 2
NCT04183868	University of Catanzaro	Type 2 Diabetes\|Cardiovascular Risk Factor	April 2016	Phase 4
NCT04221152	Kobe University\|Boehringer Ingelheim	Insulin Resistance - Type A\|Insulin Resistance - Type B\|Lipoatrophic Diabetes Mellitus\|Insulin Resistance Syndrome	February 1, 2020	Phase 3
NCT03200860	University Medical Center Groningen	Heart Failure Acute\|Heart Failure?Congestive\|Heart Failure; With Decompensation	December 18, 2017	Phase 2
NCT02863328	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	August 10, 2016	Phase 3
NCT03790787	Hua Medicine Limited	Patients	April 18, 2019	Phase 1
NCT04917692	Ohio State University\|Diacomp	type1diabetes	July 2021	Phase 4
NCT05512130	Washington University School of Medicine	Epilepsy	August 17, 2022	Early Phase 1
NCT01316341	Boehringer Ingelheim	Diabetes Mellitus, Type 2	March 2011	Phase 1
NCT05350202	Boehringer Ingelheim	Heart Failure	November 30, 2022
NCT01111318	Boehringer Ingelheim	Hepatic Insufficiency\|Healthy	July 2010	Phase 1
NCT05078879	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Crohn´s Disease\|Glycogen Metabolism\|Inflammatory Bowel Disease (IBD)	November 16, 2021	Phase 1
NCT04018365	Kobe University\|Boehringer Ingelheim	Insulin Resistance - Type A\|Insulin Resistance - Type B\|Lipoatrophic Diabetes Mellitus\|Insulin Resistance Syndrome	September 1, 2019	Phase 3
NCT01159600	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	July 2010	Phase 3
NCT03078101	Medical University of Vienna\|Attoquant Diagnostics	Diabetic Kidney Disease\|Diabetes Mellitus, Type 2\|Chronic Kidney Disease stage3\|Chronic Kidney Disease stage4	April 15, 2017	Phase 2
NCT01001962	Aristotle University Of Thessaloniki	Hypertension\|Type II Diabetes	January 2016	Phase 4
NCT02580591	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 1	December 22, 2015	Phase 3
NCT04702490	Metacrine, Inc.	NASH\|NASH - Nonalcoholic Steatohepatitis\|Type 2 Diabetes\|Diabetes Type 2\|Diabetes\|Fatty Liver\|Fatty Liver, Nonalcoholic\|NAFLD	December 15, 2020	Phase 2
NCT03867487	University of Minnesota	Non-Alcoholic Fatty Liver Disease\|NAFLD\|Pediatric NAFLD	May 1, 2019	Phase 2
NCT02401880	Profil Institut für Stoffwechselforschung GmbH	Type 2 Diabetes Mellitus	May 2015	Phase 4
NCT02632747	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 1\|Diabetes Mellitus, Type 2\|Obesity	May 10, 2016	Phase 2
NCT01111331	Boehringer Ingelheim	Healthy	May 2010	Phase 1
NCT04523064	University of Sao Paulo General Hospital	Diabetes Mellitus, Type 2\|Coronary Artery Disease\|Coronary Artery Bypass Surgery\|Acute Kidney Injury	September 22, 2020	Phase 4
NCT03510000	Samuel Lunenfeld Research Institute, Mount Sinai Hospital\|Canadian Diabetes Association\|Institut de Recherches Cliniques de Montreal\|McGill University Health Centre+Research Institute of the McGill University Health Centre	Type1diabetes	May 15, 2018	Not Applicable
NCT03128528	University of Erlangen-Nürnberg Medical School	Chronic Heart Failure	July 1, 2017	Phase 2
NCT05501483	Karolinska Institutet\|Karolinska University Hospital	Type 2 Diabetes	September 1, 2022	Not Applicable
NCT05200793	Alexandria University	Polycystic Ovary Syndrome (PCOS)	December 7, 2021	Phase 4
NCT00558571	Boehringer Ingelheim	Diabetes Mellitus, Type 2	January 2008	Phase 1
NCT03993132	Boehringer Ingelheim	Diabetes Mellitus, Type 2	October 1, 2018
NCT03093103	Centre Hospitalier Universitaire Vaudois	Nephropathy	March 16, 2017	Phase 2
NCT03008551	Hull University Teaching Hospitals NHS Trust	Polycystic Ovary Syndrome	August 18, 2017	Phase 2\|Phase 3
NCT01581658	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	April 1, 2012	Phase 1
NCT01844531	Boehringer Ingelheim	Healthy	April 2013	Phase 1
NCT05210517	Amsterdam UMC, location VUmc	Type 2 Diabetes	October 1, 2020	Phase 4
NCT04014192	Peking Union Medical College Hospital	Type 2 Diabetes Mellitus	September 1, 2019	Phase 4
NCT04670666	EMS	Type 2 Diabetes Mellitus	August 2023	Phase 3
NCT00885118	Boehringer Ingelheim	Diabetes Mellitus, Type 2	April 2009	Phase 2
NCT04639414	The Deutsche Diabetes Forschungsgesellschaft e.V.\|Boehringer Ingelheim\|German Center for Diabetes Research\|Federal Ministry of Health, Germany\|Ministry of Innovation, Science and Research in North Rhine-Westphalia\|Novo Nordisk A+S\|German Diabetes Center	Type 2 Diabetes\|Non-alcoholic Steatohepatitis (NASH)\|Non-alcoholic Fatty Liver Disease (NAFLD)	March 26, 2021	Phase 4
NCT05229796	Mutah University	Pharmacokinetic Parameters	May 17, 2021	Not Applicable
NCT04531462	Boehringer Ingelheim	Diabetes Mellitus, Type 2	October 5, 2020	Phase 4
NCT05058417	Sadat City University	Ulcerative Colitis	October 1, 2021	Phase 2
NCT02821910	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	July 20, 2016	Phase 1
NCT03208465	CHEOL WHAN LEE, M.D., Ph.D\|Asan Medical Center	Diabetes Mellitus\|Coronary Disease	August 7, 2017	Phase 4
NCT04976283	Getz Pharma	Diabetes Mellitus, Type 2\|NASH - Nonalcoholic Steatohepatitis\|NAFLD	September 15, 2021	Phase 4
NCT01289990	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	February 2011	Phase 3
NCT03448406	Boehringer Ingelheim\|Eli Lilly and Company	Heart Failure	March 20, 2018	Phase 3
NCT03485092	NHS Greater Glasgow and Clyde\|University of Glasgow	Heart Failure\|Diabetes Mellitus	March 16, 2018	Phase 4
NCT02890745	Henrik Enghusen Poulsen\|University Hospital, Gentofte, Copenhagen\|University of Copenhagen\|Rigshospitalet, Denmark	Diabetes Mellitus, Type 2	November 2016	Phase 2
NCT05553938	Yale University	Heart Failure	November 2022	Phase 1
NCT01210001	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	September 2010	Phase 3
NCT02172170	Boehringer Ingelheim	Healthy	January 2007	Phase 1
NCT03087773	Medical University of Graz\|United Arab Emirates University\|Medical University of Vienna\|Landeskrankenhaus Feldkirch\|Paracelsus Medical University\|Hospital Rudolfstiftung\|Klinikum Klagenfurt am Wörthersee\|Barmherzige Brüder Eisenstadt\|Kardinal Schwarzenberg Klinikum Schwarzach St. Veit\|Johannes Kepler University of Linz\|Landesklinikum Sankt Polten\|Landeskrankenhaus II Graz West	Acute Myocardial Infarction	May 11, 2017	Phase 3
NCT02276365	Boehringer Ingelheim	Healthy	June 2009	Phase 1
NCT05347459	Alexandria University	Type 2 Diabetes	March 2, 2022
NCT03895229	Ain Shams University\|Drug Research Centre, Cairo, Egypt	Diabetes Mellitus\|Pharmacokinetics\|Pharmacodynamics	October 1, 2018	Phase 1
NCT05036317	University Hospital, Basel, Switzerland\|Boehringer Ingelheim	Postprandial Hypoglycemia	March 11, 2022	Phase 3
NCT02172222	Boehringer Ingelheim	Healthy	July 2009	Phase 1
NCT02266472	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	November 2014	Phase 1
NCT03817463	Boehringer Ingelheim	Diabetes Mellitus, Type 2	April 15, 2019
NCT03485222	Icahn School of Medicine at Mount Sinai\|Boehringer Ingelheim\|Eli Lilly and Company	Cardiovascular Diseases	May 21, 2018	Phase 4
NCT05283057	Kasr El Aini Hospital	Glomerulonephritis\|Proteinuria	February 20, 2020	Phase 3
NCT02833415	University of Texas Southwestern Medical Center\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Obesity, Visceral	March 2016	Phase 4
NCT03852901	National Institute on Aging (NIA)\|National Institutes of Health Clinical Center (CC)	Empaglifozin\|Physiological Effects of Drugs\|Hypoglycemic Agents\|Sodium-Glucose Transporter 2 Inhibitors	March 28, 2019	Phase 1
NCT01672788	Boehringer Ingelheim	Healthy	August 2012	Phase 1
NCT02854748	Chong Kun Dang Pharmaceutical	Diabetes Mellitus, Type II	August 2016	Phase 1
NCT04642261	The University of Hong Kong\|Food and Health Bureau, Hong Kong	Non-alcoholic Fatty Liver Disease	January 1, 2021	Phase 4
NCT03198585	Morten Schou\|Herlev and Gentofte Hospital	Heart Failure With Reduced Ejection Fraction	June 29, 2017	Phase 2
NCT02172235	Boehringer Ingelheim	Healthy	April 2010	Phase 1
NCT02864914	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	March 15, 2016
NCT04203927	University of Virginia\|National Heart, Lung, and Blood Institute (NHLBI)	Type2 Diabetes\|Insulin Sensitivity	February 1, 2020	Early Phase 1
NCT01947855	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	September 2013	Phase 3
NCT03254849	Profil Institut für Stoffwechselforschung GmbH	Type 2 Diabetes Mellitus	December 8, 2017	Phase 4
NCT01131676	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	July 2010	Phase 3
NCT03030222	Saint Luke´s Health System	Heart Failure	July 5, 2017	Phase 4
NCT03912909	Royal Perth Hospital	Metabolic Syndrome\|Type 2 Diabetes Mellitus\|Obesity	August 1, 2018	Phase 4
NCT03050619	Boehringer Ingelheim\|Eli Lilly and Company	Type 2 Diabetes	September 10, 2016
NCT05140694	Seoul National University Bundang Hospital	Metabolic-associated Fatty Liver Disease\|Type 2 Diabetes	December 1, 2023	Phase 4
NCT01634100	Boehringer Ingelheim	Healthy	June 2012	Phase 1
NCT01306175	Boehringer Ingelheim	Healthy	February 2011	Phase 1
NCT05182658	Institute of Cardiology, Warsaw, Poland\|Medical University of Bialystok\|University of Eastern Finland\|Amsterdam UMC, location VUmc	Hypertrophic Cardiomyopathy\|Heart Failure	June 1, 2022	Phase 3
NCT05057819	University Hospital Inselspital, Berne	Dumping Syndrome\|Hypoglycemia, Reactive	December 1, 2021	Phase 4
NCT03642184	RenJi Hospital	New Onset Diabetes After Transplant\|Kidney Transplant; Complications	July 14, 2018	Phase 4
NCT05305495	McGill University Health Centre+Research Institute of the McGill University Health Centre	Acute Heart Failure\|Chronic Kidney Diseases	December 2022	Phase 4
NCT01984606	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	January 2015	Phase 3
NCT01167881	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	August 2010	Phase 3
NCT04098575	Boehringer Ingelheim	Diabetes Mellitus, Type 2	September 16, 2019
NCT05510115	University of Colorado, Denver\|University of Maryland	Polycystic Kidney, Autosomal Dominant	October 17, 2022	Phase 2
NCT05313529	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|Wuxi People´s Hospital\|The First Affiliated Hospital with Nanjing Medical University	Type 2 Diabetes Mellitus\|Mild Cognitive Impairment	October 8, 2022	Not Applicable
NCT02964715	University of Malaya	Type2 Diabetes\|NAFLD	November 2016	Phase 4
NCT03979352	Samuel Lunenfeld Research Institute, Mount Sinai Hospital\|McGill University Health Centre+Research Institute of the McGill University Health Centre	Type1 Diabetes Mellitus	August 1, 2019	Phase 3
NCT03227484	University Hospital Tuebingen	PreDiabetes\|Body Weight	June 9, 2017	Phase 2
NCT03113110	Medical University of Vienna	Posttransplant Diabetes Mellitus	January 15, 2017	Phase 2
NCT03226457	University of Dundee\|British Heart Foundation	Heart Failure\|Type 2 Diabetes Mellitus	December 11, 2017	Phase 4
NCT03202667	University Hospital, Basel, Switzerland	SIAD - Syndrome of Inappropriate Antidiuresis\|Hyponatremia	December 15, 2017	Phase 2\|Phase 3
NCT02172209	Boehringer Ingelheim	Healthy	January 2008	Phase 1
NCT02102932	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	May 2014	Phase 1
NCT02589626	Boehringer Ingelheim	Diabetes Mellitus, Type 2	October 29, 2015	Phase 4
NCT04215445	National University of Malaysia	Diabetic Retinopathy\|Chronic Kidney Diseases\|Diabetes Mellitus	December 1, 2019	Phase 4
NCT01328184	Boehringer Ingelheim	Healthy	April 2011	Phase 1
NCT04238702	Amsterdam UMC, location VUmc	Diabetes Mellitus, Type 2\|Diabetic Kidney Disease	November 4, 2020	Phase 4
NCT03332212	Boehringer Ingelheim\|Eli Lilly and Company	Heart Failure	March 1, 2018	Phase 3
NCT05162014	Boehringer Ingelheim	Diabetes Mellitus, Type 2	December 20, 2021
NCT05392764	Juntendo University\|Boehringer Ingelheim	Acute Heart Failure	September 10, 2022	Phase 3
NCT05430243	Alexandria University	Ascites Hepatic	April 21, 2022	Phase 2\|Phase 3
NCT04203914	Yaounde Central Hospital	Hypertension	January 10, 2017	Phase 4
NCT03639545	University Medical Centre Ljubljana	Vascular Stiffness\|Hypoglycemic Agents\|Diabetes Complications\|Diabetes Mellitus, Type 1	March 1, 2018	Phase 4
NCT01304329	Boehringer Ingelheim	Healthy	February 2011	Phase 1
NCT01248364	Boehringer Ingelheim	Diabetes Mellitus, Type 2	November 2010	Phase 2
NCT03462069	Sanofi	Diabetes Mellitus	March 12, 2018	Phase 2
NCT04243850	Amsterdam UMC, location VUmc	Diabetes Mellitus, Type 2\|Chronic Kidney Diseases	July 1, 2020	Phase 4
NCT03059056	British University In Egypt	Diabetes Mellitus	February 2, 2017	Phase 1
NCT03554200	RWTH Aachen University\|Boehringer Ingelheim	Diabetes Mellitus, Type 2\|Acute Heart Failure	June 11, 2018	Phase 2
NCT02182453	Boehringer Ingelheim	Healthy	June 2008	Phase 1
NCT04927858	Boehringer Ingelheim	Type 2 Diabetes Mellitus	April 2, 2018
NCT03504566	Steno Diabetes Center Copenhagen\|University Medical Center Groningen	Diabetic Nephropathy Type 2	November 15, 2017	Phase 4
NCT04049045	Christian Schulze\|Boehringer Ingelheim\|Zentrum für Klinische Studien Jena\|Jena University Hospital	Acute Decompensated Heart Failure	September 29, 2019	Phase 2
NCT01211197	Boehringer Ingelheim	Diabetes Mellitus, Type 2	October 2010	Phase 1
NCT03249506	Janssen Research & Development, LLC	Diabetes Mellitus, Type 2	May 12, 2016
NCT03429543	Boehringer Ingelheim	Diabetes Mellitus, Type 2	March 20, 2018	Phase 3
NCT05373004	Omar Tarek Elfarargi\|Hamad General Hospital	Diabetic Nephropathy Type 2	March 2023	Phase 2\|Phase 3
NCT05364190	October 6 University\|Cairo University\|National Heart Institute, Egypt	Chronic Heart Failure\|Acute Decompensated Heart Failure\|Diabetes Mellitus	June 4, 2022	Phase 3
NCT05139472	University of Texas Southwestern Medical Center\|Boehringer Ingelheim	Heart Failure With Preserved Ejection Fraction\|Heart Failure, Diastolic\|Diabetes Mellitus	November 9, 2021	Phase 3
NCT03027960	Yale University\|Boehringer Ingelheim	Heart Failure\|Type II; Diabetes	June 27, 2017	Phase 1
NCT01907113	Boehringer Ingelheim	Diabetes Mellitus, Type 2	July 2009	Phase 1
NCT02998970	Unity Health Toronto\|Boehringer Ingelheim	Diabetes\|Cardiovascular Disease	January 2017	Phase 4
NCT04583813	Miulli General Hospital	Atrial Fibrillation\|Heart Failure\|Obesity\|Diabetes Mellitus	September 2021	Phase 4
NCT04541797	The University of Hong Kong	Type 2 Diabetes\|Microvascular Coronary Artery Disease	October 1, 2020	Not Applicable
NCT05036421	Ain Shams University	Pharmacogenomic\|Pharmacokinetics	February 15, 2022	Phase 3
NCT04853615	Fayoum University\|Cairo University	SGLT2i Kideny Protection Against Contrast in Diabetic Kidney	July 1, 2021
NCT04910178	Asmaa Abdelfattah Elsayed\|Beni-Suef University	Diabetes Type 2\|NAFLD	January 1, 2021	Phase 4
NCT03565458	LG Chem	Type 2 Diabetes Mellitus	April 5, 2018	Phase 1
NCT02932436	Johannes Gutenberg University Mainz\|Boehringer Ingelheim	Diabetes Mellitus, Type 2\|Diastolic Dysfunction	October 10, 2016	Phase 4
NCT01649297	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	October 2012	Phase 2
NCT02792400	University Hospital, Gentofte, Copenhagen\|Eli Lilly and Company	Type 2 Diabetes	May 2016	Not Applicable
NCT03646292	Yonsei University	NAFLD - Nonalcoholic Fatty Liver Disease\|Type2 Diabetes	December 19, 2018	Phase 4
NCT01193218	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	September 2010	Phase 2
NCT02577315	Boehringer Ingelheim	Healthy	September 2015	Phase 1
NCT05417646	Steno Diabetes Center Copenhagen\|University of Copenhagen	Maturity-Onset Diabetes of the Young, Type 3\|Type 2 Diabetes	June 22, 2022	Not Applicable
NCT05254002	Bayer	Type 2 Diabetes Mellitus\|Chronic Kidney Disease	June 23, 2022	Phase 2
NCT02758171	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	May 17, 2016	Phase 1
NCT05600387	Zhijun Sun\|Shengjing Hospital	Heart Failure\|Heart Failure With Preserved Ejection Fraction\|Heart Failure With Mid Range Ejection Fraction	November 5, 2022	Phase 4
NCT03215069	Mount Sinai Hospital, Canada\|Boehringer Ingelheim	Gestational Diabetes	July 1, 2018	Phase 3
NCT05084235	Jacob Moller\|Danish Heart Foundation\|Herlev and Gentofte Hospital\|University Hospital Bispebjerg and Frederiksberg\|Hillerod Hospital, Denmark\|Rigshospitalet, Denmark\|Odense University Hospital	Heart Failure\|Obesity	September 2, 2021	Phase 2
NCT03464045	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	November 16, 2016
NCT02172248	Boehringer Ingelheim	Healthy	January 2009	Phase 1
NCT01276288	Boehringer Ingelheim	Diabetes Mellitus, Type 2	January 2011	Phase 1
NCT03933956	Singapore General Hospital\|Duke-NUS Graduate Medical School	Diabetic Nephropathies	January 9, 2020	Phase 3
NCT01924767	Boehringer Ingelheim	Diabetes Mellitus, Type 2	July 2007	Phase 1
NCT05232071	Inventiva Pharma	NASH - Nonalcoholic Steatohepatitis\|Diabetes Mellitus, Type 2	June 29, 2022	Phase 2
NCT05102071	Boehringer Ingelheim	Diabetes Mellitus, Type 2\|Cardiovascular Diseases	November 1, 2021
NCT01164501	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2\|Renal Insufficiency	July 2010	Phase 3
NCT03363464	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	October 16, 2017
NCT04295005	Boehringer Ingelheim	Diabetes Mellitus, Type 2	November 16, 2020
NCT03764631	Boehringer Ingelheim	Diabetes Mellitus, Type 2	September 26, 2018
NCT04061200	Steno Diabetes Center Copenhagen\|Novo Nordisk A+S	Type 2 Diabetes With Renal Manifestations	November 1, 2019	Phase 4
NCT04907214	Vanderbilt University Medical Center	Obesity\|Pre-diabetes	July 29, 2021	Phase 1\|Phase 2
NCT05444153	Novo Nordisk A+S	Diabetes Mellitus, Type 2	October 6, 2022	Phase 3
NCT01451775	Boehringer Ingelheim	Healthy	October 2011	Phase 1
NCT01177813	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	July 2010	Phase 3
NCT05103306	Chungbuk National University Hospital	Diabetes Mellitus, Type 2	January 2017
NCT03057977	Boehringer Ingelheim\|Eli Lilly and Company	Heart Failure	March 6, 2017	Phase 3
NCT04143581	Mario Negri Institute for Pharmacological Research\|Boehringer Ingelheim	Obesity\|Non-diabetic Chronic Kidney Disease	September 3, 2021	Phase 2
NCT02172196	Boehringer Ingelheim	Healthy	May 2009	Phase 1
NCT01284621	Boehringer Ingelheim	Healthy	January 2011	Phase 1
NCT03771781	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Type 2 Diabetes	April 16, 2018	Not Applicable
NCT00749190	Boehringer Ingelheim	Diabetes Mellitus, Type 2	August 2008	Phase 2
NCT05164263	Getz Pharma	Type II Diabetes Mellitus\|Efficacy, Self\|Safety Issues	April 1, 2021	Phase 4
NCT04138251	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Glycogen Storage Disease Type I\|Glucose 6 Phosphatase Deficiency	June 20, 2019	Phase 2
NCT02686476	Medanta, The Medicity, India	Non Alcoholic Fatty Liver Disease	March 2016	Not Applicable
NCT02728453	Hannover Medical School\|Boehringer Ingelheim	Diabetes Mellitus Type 2	April 27, 2016	Phase 4
NCT03050229	Jichi Medical University\|Boehringer Ingelheim\|Eli Lilly and Company	Nocturnal Hypertension\|T2DM (Type 2 Diabetes Mellitus)	January 2017	Phase 4
NCT03594110	Boehringer Ingelheim\|Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)\|Eli Lilly and Company	Chronic Kidney Disease	January 31, 2019	Phase 3
NCT01867307	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2\|Healthy	June 2013	Phase 2
NCT03448419	Boehringer Ingelheim\|Eli Lilly and Company	Heart Failure	March 20, 2018	Phase 3
NCT03877406	Seoul National University Bundang Hospital	Diabetes Mellitus\|Fat; Intolerance, Pancreas	August 1, 2018	Phase 4
NCT03351478	Lexicon Pharmaceuticals\|Sanofi	Type 2 Diabetes Mellitus	November 27, 2017	Phase 3
NCT04918407	Shahid Beheshti University of Medical Sciences	Kidney Transplant; Complications	January 1, 2022	Not Applicable
NCT01195675	Boehringer Ingelheim	Healthy	August 2010	Phase 1
NCT03060980	Intarcia Therapeutics	Diabetes Mellitus, Type 2	March 3, 2017	Phase 3
NCT05233163	Columbia University	Transthyretin Amyloid Cardiomyopathy	March 14, 2022	Phase 4
NCT04431141	Handok Inc.	Type 2 Diabetes Mellitus	September 15, 2020	Phase 1
NCT05147090	The University of Hong Kong\|Research Grant Council	Chronic Hepatitis b\|NAFLD\|Cirrhosis\|Fibrosis, Liver\|Empagliflozin\|SGLT2 Inhibitors	January 2, 2022	Phase 4
NCT04662866	Oslo University Hospital\|The Research Council of Norway\|Norwegian Diabetes Association\|South-Eastern Norway Regional Health Authority\|University of Oslo\|University Hospital, Akershus\|Vestre Viken Hospital Trust\|University of Glasgow	Impaired Glucose Tolerance\|Insulin Sensitivity\|Glucose Metabolism Disorders	February 10, 2021	Phase 2
NCT02782624	Boehringer Ingelheim	Healthy	September 2009	Phase 1
NCT03200782	University Hospital, Basel, Switzerland	Postprandial Hypoglycemia\|Bariatric Surgery\|Late Dumping Syndrome	May 30, 2017	Not Applicable
NCT00881530	Boehringer Ingelheim	Diabetes Mellitus, Type 2	March 2009	Phase 2
NCT05028140	EMS	Type II Diabetes	September 2022	Phase 3
NCT02471963	University of Erlangen-Nürnberg Medical School	Diabetes Mellitus Type 2	December 2014	Phase 3
NCT05556044	Chinese University of Hong Kong	Acute Heart Failure	September 27, 2022	Phase 3
NCT03259490	Boehringer Ingelheim\|Eli Lilly and Company	Healthy	August 31, 2017	Phase 1
NCT04157751	Boehringer Ingelheim\|Eli Lilly and Company	Heart Failure	May 18, 2020	Phase 3
NCT01734785	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	January 2013	Phase 3
NCT03157414	Oslo University Hospital	Diabetes Mellitus\|Renal Insufficiency\|Safety Issues	November 7, 2016	Phase 4
NCT02489968	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	May 12, 2015	Phase 3
NCT01306214	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2\|Obesity	February 2011	Phase 3
NCT01368081	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	May 2011	Phase 3
NCT02874807	University Hospital, Basel, Switzerland	SIADH	September 5, 2016	Phase 2\|Phase 3
NCT05610956	Tanta University	Ulcerative Colitis	December 1, 2022	Early Phase 1
NCT05360615	Chulalongkorn University	Empagliflozin in Post AKI Stage 2-3	July 1, 2022	Phase 1
NCT01778049	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	January 2013	Phase 3
NCT04233801	Boehringer Ingelheim	Diabetes Mellitus, Type 2	April 15, 2020	Phase 3
NCT04143321	Isfahan University of Medical Sciences	Diabetes Mellitus	September 10, 2018	Phase 4
NCT04117763	University of Sao Paulo	Diabetes Mellitus, Type 2\|Coronary Heart Disease\|Arrythmia, Cardiac	October 4, 2019	Phase 4
NCT04520646	Huashan Hospital	Acromegaly\|Cardiomyopathies	September 1, 2020	Not Applicable
NCT04215536	Brigham and Women´s Hospital	Diabetes	July 8, 2019
NCT03151343	Caroline M Kistorp\|Danish Heart Foundation\|Herlev and Gentofte Hospital\|Rigshospitalet, Denmark	Type2 Diabetes Mellitus	March 29, 2017	Phase 3
NCT03492580	Janssen Research & Development, LLC	Diabetes Mellitus, Type 2\|Cardiovascular Diseases	February 22, 2018
NCT03057951	Boehringer Ingelheim\|Eli Lilly and Company	Heart Failure	March 2, 2017	Phase 3
NCT05132023	Genuine Research Center, Egypt\|Hikma Pharma	Healthy	March 26, 2019	Phase 1
NCT04535960	University Health Network, Toronto	Type 2 Diabetes Mellitus	January 24, 2019	Phase 2
NCT04961931	Medical University of Lodz	Chronic Kidney Disease stage3	January 1, 2019	Not Applicable
NCT02121483	Boehringer Ingelheim\|Eli Lilly and Company	Diabetes Mellitus, Type 2	June 2014	Phase 1
NCT05584319	Zhijun Sun\|Shengjing Hospital	Heart Failure\|Heart Failure With Preserved Ejection Fraction\|Heart Failure With Mid Range Ejection Fraction	November 5, 2022	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 110.89 mM ; Need ultrasonic)

H ₂ O : 0.11 mg/mL ( 0.24 mM ; Need ultrasonic and warming)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2177 mL	11.0887 mL	22.1774 mL
5 mM	0.4435 mL	2.2177 mL	4.4355 mL
10 mM	0.2218 mL	1.1089 mL	2.2177 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 0.5%HPMC

Solubility: 5 mg/mL (11.09 mM); Suspension solution; Need ultrasonic
2.

Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

Solubility: ≥ 2.87 mg/mL (6.36 mM); Clear solution
3.

Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.87 mg/mL (6.36 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution
5.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution
6.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90.
[2] Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391.
[3] Nikole J.ByrneBSc, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC Basic Transl Sci. 2017 Aug;2(4):347-354.
[4] Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943.

Synonyms

D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-

(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol

Empagliflozin

BI 10773

Jardiance

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart